Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biothera has announced positive results of Imprime PGG in combination with cetuximab (Erbitux), carboplatin and paclitaxel in a Phase II non-small cell lung cancer (NSCLC) clinical trial.
Subscribe to our email newsletter
Imprime PGG is an immunomodulatory drug, used as a treatment for cancer.
The open label multicentre randomised trial involving 90 patients assessed the safety and efficacy of Imprime PGG along with cetuximab and a standard chemotherapy regimen (carboplatin and paclitaxel) compared to cetuximab alone with the same chemotherapy.
The study intended to determine the anti-tumour effects of Imprime PGG with cetuximab and standard chemotherapy, based on overall response rate as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST).
Imprime PGG, at present is being studied in a Phase III trial in KRAS wild type colorectal cancer and several Phase II clinical trials in non-small cell lung cancer and chronic lymphocytic leukemia.